Novo Nordisk A/S stays a Buy as oral Wegovy surges and the GLP-1 pipeline strengthens; an attractive 2028 P/E suggests upside. Click to read more on NVO.
Get this week's Dividend Champions, Contenders & Challengers update: dividend changes, upcoming ex-dividend dates, and pay dates. Read the full list here.
Coty Inc. beat Q4 revenue, but weak guidance, FY2027 uncertainty, and possible Consumer Beauty divestiture raise risk--click to read the analysis before investing.